微生态制剂协同抗生素对ICU重症肺感染的疗效观察

Efficacy of Probiotics combined with antibiotics in ICU patients with severe pulmonary infection

目的观察微生态制剂联合抗生素治疗ICU重症肺感染的临床疗效。方法选取我院ICU病房2012年3月至2014年3月收治的56例重症肺感染患者为研究对象,随机将其分为两组,每组28例,对照组患者行单纯抗生素治疗,观察组患者给予微生态制剂联合抗生素治疗,对两组治疗效果及治疗前后各指标进行比较。结果观察组患者痊愈5例(17.86%),好转18例(64.28%),治疗总有效率为82.14%;对照组患者痊愈1例(3.57%),好转16例(57.14%),治疗总有效率为60.71%,观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。另外,两组患者治疗后PO2、PCO2及WBC明显优于治疗前,且观察组治疗后患者的PO2[(80.30±9.26)mmHg]、PCO2[(45.53±4.27)mmHg]及WBC[(8.85±3.62)G/L]指标明显优于对照组的(70.33±8.75)mmHg、(51.61±5.40)mmHg及(10.81±4.00)G/L,差异有统计学意义(P<0.05)。结论相比单纯抗生素治疗,微生态制剂联合抗生素治疗效果明显,能帮助缓解和缩短肺感染症状,可作为重症肺感染治疗的主要手段。

Objective To observe the clinical effect of probiotics combined with antibiotics in treatment of severe pulmonary infection in ICU patients.Methods 56 severe pulmonary infection patients admitted in the ICU of our hospital from March 2012 to March 2014 were included and randomly divided into the control group or observation group with 28 patients in each group.The control group was given antibiotic therapy,while the observation group was given the same treatment combined with probiotic.The treatment effect and the symptom indexes before and after the treatment were compared between the two groups.Results The total efficiency rate in Observation group was 82.14%including 5cases cured（17.86%）and 18 cases improved（64.28%）,while in the control group,there were 1case cured（3.57%）and 16 cases improved（57.14%）,resulting a total efficiency rate of 60.71%.The difference in total efficiency rate between the two groups was statistically significant（P〈0.05）.In addition,the PO2,PCO2 and WBC were better after treatment in both groups,with those of the observation group significantly superior to those of the control group（P〈0.05）.Conclusion Compared with antibiotic treatment,probiotics combined with antibiotic therapy has better effect,which can effectively alleviate the symptoms of lung infection,and can be used as one of the major means of treatment for severe lung infection.